@JAMAOnc profile picture
JAMA Oncology @JAMAOnc

JAMA Oncology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications.

Joined September 2014
  • Tweets 18,744
  • Following 510
  • Followers 50,473
2,413 Photos and videos
This JAMA Oncology Patient Page discusses benefits and risks of local consolidative therapy for metastatic #LungCancer and which patients might be considered for this treatment. ja.ma/4vaMtIp
Local consolidative therapy (LCT) in lung cancer is explained. A human torso diagram shows lungs with cancer spots and a liver spot. Text outlines LCT benefits (control spread, delay growth), risks (fatigue, lung inflammation), eligibility (good response, few spots), timing, and care team involvement. LCT requires careful patient selection.

ALT Local consolidative therapy (LCT) in lung cancer is explained. A human torso diagram shows lungs with cancer spots and a liver spot. Text outlines LCT benefits (control spread, delay growth), risks (fatigue, lung inflammation), eligibility (good response, few spots), timing, and care team involvement. LCT requires careful patient selection.

1
16
42
3,144
A 58-year-old woman with #BreastCancer with multiple prior courses of systemic treatments presented with hypotension, hypoxia, significant polyuria, and polydipsia. Mild thickening of the pituitary stalk was seen. ✍️ What is your diagnosis? ja.ma/4aGgUOc
1
8
11
2,120
This Special Communication provides consensus recommendations on the acquisition, interpretation, and reporting of prostate magnetic resonance imaging for cancer screening. ja.ma/49XvIrE
3
4
1,282
Avelumab combined with methotrexate resulted in >95% durable remission and preserved #fertility in low-risk gestational trophoblastic #tumors, with a manageable safety profile. ja.ma/3S0k60N
1
6
17
1,800
Sequential radiotherapy and immunotherapy (#iRT) provided longer overall survival than concurrent iRT for newly diagnosed advanced non–small cell lung cancer, with additional benefit from chemotherapy. ja.ma/4oh4KRG
Kaplan-Meier curves show real-world overall survival for refractory NSCLC treated with immunotherapy plus radiotherapy, comparing \"with\" vs. \"without chemotherapy\" (overlap-weighted & unweighted). Crude HR 1.11, Adjusted HR 0.85. A table of number at risk is below.

ALT Kaplan-Meier curves show real-world overall survival for refractory NSCLC treated with immunotherapy plus radiotherapy, comparing \"with\" vs. \"without chemotherapy\" (overlap-weighted & unweighted). Crude HR 1.11, Adjusted HR 0.85. A table of number at risk is below.
12
28
2,574
This JAMA Oncology Patient Page discusses benefits and risks of local consolidative therapy for metastatic #LungCancer and which patients might be considered for this treatment. ja.ma/3Qq28Ex
Local consolidative therapy (LCT) in lung cancer is explained. A human torso diagram shows lungs with cancer spots and a liver spot. Text outlines LCT benefits (control spread, delay growth), risks (fatigue, lung inflammation), eligibility (good response, few spots), timing, and care team involvement. LCT requires careful patient selection.

ALT Local consolidative therapy (LCT) in lung cancer is explained. A human torso diagram shows lungs with cancer spots and a liver spot. Text outlines LCT benefits (control spread, delay growth), risks (fatigue, lung inflammation), eligibility (good response, few spots), timing, and care team involvement. LCT requires careful patient selection.

1
11
21
1,704
Among patients with early age–onset #ColorectalCancer in Texas, treatment delays longer than six weeks were associated with reduced survival, and language barriers represented a major risk factor contributing to delayed initiation of definitive therapy. ja.ma/43bcZoB
1
7
18
2,260
Sequential radiotherapy and immunotherapy (#iRT) provided longer overall survival than concurrent iRT for newly diagnosed advanced non–small cell lung cancer, with additional benefit from chemotherapy. ja.ma/4fqf0ER
Kaplan-Meier curves show real-world overall survival for refractory NSCLC treated with immunotherapy plus radiotherapy, comparing \"with\" vs. \"without chemotherapy\" (overlap-weighted & unweighted). Crude HR 1.11, Adjusted HR 0.85. A table of number at risk is below.

ALT Kaplan-Meier curves show real-world overall survival for refractory NSCLC treated with immunotherapy plus radiotherapy, comparing \"with\" vs. \"without chemotherapy\" (overlap-weighted & unweighted). Crude HR 1.11, Adjusted HR 0.85. A table of number at risk is below.

3
14
29
2,719
A phase 3 trial shows serplulimab plus chemotherapy improved overall survival and 4-year survival rates vs chemotherapy alone in extensive-stage small cell #LungCancer, with durable benefit and manageable safety. ja.ma/4uQS5Y4
1
6
9
1,413
Oral upadacitinib achieved rapid resolution and pruritus relief in severe immune checkpoint inhibitor–related #Dermatitis, with no serious treatment-related adverse events. ja.ma/3ROLSxb
JAMA Oncology Research Letter: \"Upadacitinib for Immune Checkpoint Inhibitor-Related Dermatitis: A Nonrandomized Clinical Trial.\" Authors: Chengshui Chen, Xinyu Liang, Zheng Peng et al. Published Online: March 5, 2026. doi:10.1001/jamaoncol.2026.0136.

ALT JAMA Oncology Research Letter: \"Upadacitinib for Immune Checkpoint Inhibitor-Related Dermatitis: A Nonrandomized Clinical Trial.\" Authors: Chengshui Chen, Xinyu Liang, Zheng Peng et al. Published Online: March 5, 2026. doi:10.1001/jamaoncol.2026.0136.
7
22
2,138
A meta-analysis found first-line chemoimmunotherapy provided longer overall and progression-free survival than PD-(L)1 inhibitor monotherapy in advanced #NSCLC with high #PDL1, though with greater toxicity. ja.ma/4o4nvaH
2
22
49
21,106
A meta-analysis found first-line chemoimmunotherapy provided longer overall and progression-free survival than PD-(L)1 inhibitor monotherapy in advanced #NSCLC with high #PDL1, though with greater toxicity. ja.ma/4fn6KW3
13
48
190,905
This JAMA Oncology Patient Page discusses benefits and risks of local consolidative therapy for metastatic #LungCancer and which patients might be considered for this treatment. ja.ma/4o2PMi1
12
18
1,349
Oral upadacitinib achieved rapid resolution and pruritus relief in severe immune checkpoint inhibitor–related #Dermatitis, with no serious treatment-related adverse events. ja.ma/4dtzNEG

Upadacitinib for Immune Checkpoint Inhibitor–Related Dermatitis

This nonrandomized clinical trial examines the safety and efficacy of oral upadacitinib in the treatment of patients with severe immune checkpoint inhibitor–related dermatitis.

jamanetwork.com
1
6
919
From @JAMA_current: In resected non-small cell lung #cancer, adjuvant #nivolumab following standard care was not associated with improved survival or recurrence risk compared with observation, even in #tumors with high PD-L1 expression. #ASCO26 @ASCO ja.ma/4x1rJ7h
1
4
780
🌟Fovinaciclib for First‑Line Therapy for Advanced Breast Cancer: A Randomized Clinical Trial, presented today at #ASCO26 📖 Free to read online from @JAMAOnc ja.ma/4eckHFa
2
4
737
A phase 3 trial demonstrated that fovinaciclib plus aromatase inhibitor showed significant and clinically improved progression-free survival with manageable safety in hormone receptor–positive, ERBB2-negative advanced #BreastCancer. #ASCO26 @ASCO ja.ma/43BlFoq
1
2
617
A 69-year-old male patient presented with worsening new-onset oral ulcerations and pain. He had myelodysplastic syndrome and underwent an allogeneic hematopoietic stem cell transplant 18 months prior. What is your diagnosis? See the answer: ja.ma/4wQ836n

Extensive Oral Ulcerations After Stem Cell Transplant

A 69-year-old male patient presented with worsening new-onset oral ulcerations and pain. He had myelodysplastic syndrome and underwent an allogeneic hematopoietic stem cell transplant 18 months...

jamanetwork.com
2
921
✨Impact of Population‑Based Pathogenic Variant Testing on Risk‑Based Breast Screening Recommendations: A Secondary Analysis of the WISDOM Study, presented today at #ASCO26 📖 Free to read online from @JAMAOnc ja.ma/3RQ16C0
1
1
760
Among women with breast cancer gene pathogenic variants (PV), most would not have received high-risk screening based on clinical or polygenic risk, supporting the need for germline PV testing in risk-based #BreastCancer screening. #ASCO26 @ASCO ja.ma/4fXbCkO
Sankey plots from the WISDOM Study show breast screening assignments by age group. Panel A (40-49 y) & B (50-74 y) illustrate the flow from BCSC model to BCSC-PRS model to Actual assignment. Node colors represent high-risk, annual, biennial mammography, and no/stop screening.

ALT Sankey plots from the WISDOM Study show breast screening assignments by age group. Panel A (40-49 y) & B (50-74 y) illustrate the flow from BCSC model to BCSC-PRS model to Actual assignment. Node colors represent high-risk, annual, biennial mammography, and no/stop screening.
11
13
3,937
Load more